Nevertheless, even though AMPK serves as a promising target for obesity in a number of animal models, plenty of difficulties need to be addressed before the clinical application of drugs that modify AMPK in treating human obesity. Here, PRKAA2 is linked to obesity due to melanocortin 4 receptor deficiency.